The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
Open accessAbstract
Myeloid-derived suppressor cells (MDSC) play a key immunosuppressive role in various types of cancer, including head and neck squamous cell carcinoma (HNSCC). In this study, we characterized CD14+HLA-DR(-/lo) cells sorted from the tumors, draining lymph nodes, and peripheral blood of HNSCC patients. CD14+HLA-DR(-/lo) cells were phenotyped as CD11b+, CD33+, CD34+, arginase-I+, and ROS+. In all 3 compartments, they suppressed autologous, antigen-independent T cell proliferation in a differential manner. The abundance of MDSC correlated with stage, but did not correlate with previous treatment with radiation or subsites of HNSCC. Interestingly, MDSC from all 3 compartments showed high phosphorylated STAT3 levels that correlated with arginase-I expression levels and activity. Stattic, a STAT3-specific inhibitor, and STAT3-targeted siRNA abrogated MDSC’s suppressive function. Inhibition of STAT3 signaling also resulted in decreased arginase-I activity. Analysis of the human arginase-I promoter region showed multiple STAT3-binding elements, and ChIP demonstrated that phosphorylated STAT3 binds to multiple sites in the arginase-I promoter. Finally, rescue of arginase-I activity after STAT3 blockade restored MDSC’s suppressive function. Taken together, these results demonstrate that the suppressive function of arginase-I in both infiltrating and circulating MDSC is a downstream target of activated STAT3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Self-citationVISTA: computational tools for comparative genomics
Frazer, K. A., Pachter, L., Poliakov, A., Rubin, E. M., & Dubchak, I. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh458 · Cited by 2,798
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595
Self-citationMovahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,031
Self-citationChalmin, F., Ladoire, S., Mignot, G., Vincent, J., Bruchard, M., Remy-Martin, J.-P., Boireau, W., Rouleau, A., Simon, B., Lanneau, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40483 · Cited by 998
Cheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M., Nacken, W., Sorg, C., Vogl, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080132 · Cited by 902
Zea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 851
Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor
Marigo, I., Bosio, E., Solito, S., Mesa, C., Fernandez, A., Dolcetti, L., Ugel, S., Sonda, N., Bicciato, S., Falisi, E., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.010 · Cited by 850
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 842
Self-citationThe Terminology Issue for Myeloid-Derived Suppressor Cells
Gabrilovich, D. I., Bronte, V., Chen, S.-H., Colombo, M. P., Ochoa, A., Ostrand-Rosenberg, S., & Schreiber, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3037 · Cited by 835
Rodriguez, P. C., Ernstoff, M. S., Hernandez, C., Atkins, M., Zabaleta, J., Sierra, R., & Ochoa, A. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1921 · Cited by 773
SERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand-Rosenberg, S., & Srikrishna, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4666 · Cited by 725
Rodríguez, P. C., & Ochoa, A. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00608.x · Cited by 719
Delano, M. J., Scumpia, P. O., Weinstein, J. S., Coco, D., Nagaraj, S., Kelly-Scumpia, K. M., O'Malley, K. A., Wynn, J. L., Antonenko, S., Al-Quran, S. Z., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062602 · Cited by 652
Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., & Rivoltini, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5829 · Cited by 647
Hoechst, B., Voigtlaender, T., Ormandy, L., Gamrekelashvili, J., Zhao, F., Wedemeyer, H., Lehner, F., Manns, M. P., Greten, T. F., & Korangy, F. (2009) · Hepatology · doi:10.1002/hep.23054 · Cited by 643
Myeloid-derived suppressor cell heterogeneity and subset definition
Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., & Bronte, V. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.021 · Cited by 630
Kumar, B., Cordell, K. G., Lee, J. S., Worden, F. P., Prince, M. E., Tran, H. H., Wolf, G. T., Urba, S. G., Chepeha, D. B., Teknos, T. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7662 · Cited by 612
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., & Bronte, V. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00602.x · Cited by 608
Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A., & Middleton, G. W. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1028-0 · Cited by 575
Determination of arginase activity in macrophages: a micromethod
Corraliza, I. M., Campo, M. L., Soler, G., & Modolell, M. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90027-2 · Cited by 540
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
Bharti, A. C., Donato, N., & Aggarwal, B. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3863 · Cited by 508
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
Kusmartsev, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4880 · Cited by 445
STAT3 SIGNALING: Anticancer Strategies and Challenges
Johnston, P. A., & Grandis, J. R. (2011) · Molecular Interventions · doi:10.1124/mi.11.1.4 · Cited by 406
Myeloid derived suppressor cells in human diseases
Greten, T. F., Manns, M. P., & Korangy, F. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.003 · Cited by 398
Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V., & Kiessling, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3767 · Cited by 382
Adenosine promotes alternative macrophage activation via A2A and A2B receptors
Csóka, B., Selmeczy, Z., Koscsó, B., Németh, Z. H., Pacher, P., Murray, P. J., Kepka‐Lenhart, D., Jr., S. M. M., Gause, W. C., Leibovich, S. J., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-190934 · Cited by 376
Solito, S., Falisi, E., Diaz-Montero, C. M., Doni, A., Pinton, L., Rosato, A., Francescato, S., Basso, G., Zanovello, P., Onicescu, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-325753 · Cited by 337
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318
Liu, C.-Y., Wang, Y.-M., Wang, C.-L., Feng, P.-H., Ko, H.-W., Liu, Y.-H., Wu, Y.-C., Chu, Y., Chung, F.-T., Kuo, C.-H., et al. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0634-0 · Cited by 313
IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients
Mandruzzato, S., Solito, S., Falisi, E., Francescato, S., Chiarion-Sileni, V., Mocellin, S., Zanon, A., Rossi, C. R., Nitti, D., Bronte, V., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803831 · Cited by 304
Talmadge, J. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0182 · Cited by 285
Pak, A. S., Wright, M. A., Matthews, J. P., Collins, S. L., Petruzzelli, G. J., & Young, M. R. I. (1995) · PubMed · Cited by 271
STAT3 controls myeloid progenitor growth during emergency granulopoiesis
Zhang, H., Nguyen-Jackson, H., Panopoulos, A. D., Li, H. S., Murray, P. J., & Watowich, S. S. (2010) · Blood · doi:10.1182/blood-2009-12-259630 · Cited by 232
Self-citationMyeloid-derived Suppressor Cells in Cancer Patients: A Clinical Perspective
Montero, A. J., Diaz-Montero, C. M., Kyriakopoulos, C. E., Bronte, V., & Mandruzzato, S. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318242169f · Cited by 202
CCL2 Blockade Augments Cancer Immunotherapy
Fridlender, Z. G., Buchlis, G., Kapoor, V., Cheng, G., Sun, J., Singhal, S., Crisanti, M. C., Wang, L.-C. S., Heitjan, D., Snyder, L. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2326 · Cited by 193
Qualls, J. E., Neale, G., Smith, A. M., Koo, M.-S., DeFreitas, A. A., Zhang, H., Kaplan, G., Watowich, S. S., & Murray, P. J. (2010) · Science Signaling · doi:10.1126/scisignal.2000955 · Cited by 167
Self-citationTu, S. P., Jin, H., Shi, J. D., Zhu, L. M., Suo, Y., Lu, G., Liu, A., Wang, T. C., & Yang, C. S. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0247 · Cited by 165
Rotondo, R., Bertolotto, M. B., Barisione, G., Astigiano, S., Mandruzzato, S., Ottonello, L. C., Dallegri, F., Bronte, V., Ferrini, S., & Barbieri, O. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1109737 · Cited by 148
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck
Sharafinski, M. E., Ferris, R. L., Ferrone, S., & Grandis, J. R. (2010) · Head & Neck · doi:10.1002/hed.21365 · Cited by 138
Chikamatsu, K., Sakakura, K., Toyoda, M., Takahashi, K., Yamamoto, T., & Masuyama, K. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02248.x · Cited by 108
Gros, A., Turcotte, S., Wunderlich, J. R., Ahmadzadeh, M., Dudley, M. E., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1108 · Cited by 88
Chen, C., Chen, W., Lu, C.-H., Wang, W., Lin, P.-Y., Lee, K., & Chen, M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.09.059 · Cited by 69
Argiris, A. E., Lee, S. C., Feinstein, T. M., Thomas, S. M., Branstetter, B. F., Seethala, R. R., Wang, L., Gooding, W. E., Grandis, J. R., & Ferris, R. L. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.07.034 · Cited by 50
Albesiano, E., Davis, M. B., See, A. P., Han, J. E., Lim, M. K., Pardoll, D. M., & Kim, Y. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4058 · Cited by 29
Self-citation
Cited by
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Xiong, J., He, J., Zhu, J., Pan, J., Liao, W., Ye, H., Wang, H., Song, Y., Du, Y., Cui, B., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.02.033 · Cited by 804
Zhao, H., Shang, Q., Pan, Z., Bai, Y., Li, Z., Zhang, H., Zhang, Q., Guo, C., Zhang, L., & Wang, Q. (2018) · Diabetes · doi:10.2337/db17-0356 · Cited by 657
Self-citation
Metadata
- Authors
- Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., Blosser, R. L., Tam, A. J., Bruno, T., Zhang, H., Pardoll, D., & Kim, Y.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-03-01
- Volume
- 123
- Issue
- 4
- Pages
- 1580-1589
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2046764077
- Cited by
- 507
- References
- 53
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.